News

FDA advisors have recommended approval of a 60-mg dose of edoxaban (Daiichi Sankyo), a once-daily anticoagulant that inhibits Factor Xa, for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function.

Meningococcal group B vaccine (Trumenba, Pfizer) has been granted accelerated approval by FDA as the first vaccine licensed in the United States for active immunization to prevent invasive meningococcal B disease from Neisseria meningitidis serogroup B.

Americans in 2013 spent a little more on medical services from the prior year, but utilized them less, according to a new report by the Health Care Cost Institute (HCCI).

A new Kaiser health tracking poll shows 90% of uninsured Americans are not aware of the Affordable Care Act’s (ACA’s) next open enrollment period.

Public-private partnerships are proving to be an effective structure for funding and governing patient registries.

The three giants driving America’s $3 trillion healthcare economy–health insurers, hospital systems, and pharmaceutical companies–all face the same dilemma: how to effectively engage customers to earn trust and improve the consumer healthcare experience.

FDA has approved sotalol hydrochloride oral solution (Sotylize, Arbor Pharamceuticals) for the treatment of documented life-threatening ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with a history of highly symptomatic atrial fibrillation/flutter.

Hospital pharmacies play an essential role in the nation’s healthcare system, and these days, are expected to add value to every aspect of a hospital's strategic agenda.

Following the lead of the CMS, healthcare is waking up to the use of rewards to motivate consumers to get healthy.

With more than 40,000 health and wellness apps on the market today, consumers of all ages are responding to health care they can access on-the-go.

America’s health care system is going through transformational changes. Price transparency – providing consumers cost information before services are received – is a significant force in today’s system.

When Congress voted in March to push back the ICD-10 deadline to at least Oct. 1, 2015, emotions were mixed from payers and providers across the industry.

The Ebola outbreak has taught us that the health systems in West Africa are under-resourced and vulnerable. Scaling up capability of local healthcare provision is an important consideration for control of this virus, and drug makers are gearing up to expedite development of Ebola vaccines.

FDA has approved Antihemophilic Factor (Recombinant), Porcine Sequence] (Obizur, Baxter) for the treatment of bleeding episodes in adults with acquired hemophilia A.

Triple-negative breast cancer (TNBC) represents just under 15% of all breast cancer (BC) cases, according to IMS’ epidemiologic analysis. It carries a bleaker prognosis than other forms of BC. These facts are well-known. Much else about the disease is unknown, however; indeed, it’s probably a mistake to think of TNBC cancer as “a” disease at all.

FDA has approved an updated labeling of morphine sulfate/naltrexone hydrochloride (Embeda, Pfizer) extended release capsules, CII, to include abuse-deterrent properties

An FDA advisory committee has voted to keep the boxed warning for varenicline (Chantix, Pfizer) that states that the drug may cause serious neuropsychiatric events.

Enrollees in health insurance plans that don’t comply with the Affordable Care Act (ACA) have begun receiving notices of cancellation, one year after getting a reprieve.

Patients who saw a physician assistant (PA) in the past year give high marks to the interaction, according to a new Harris Poll.

A surge in ER visits and hospitalization rates on the part of newly-insured Medicaid patients is a mostly temporary phenomenon created by pent-up demand, according to a report by UCLA’s Center for Health Policy Research.

Breast cancer is the second most common cancer in the world, and the most common cancer in women. In 2013, approximately 261,000 women were diagnosed with this disease in the United States alone.1 When diagnosed in the earliest stages, such as ductal carcinoma in situ and stage 1, the 5-year survival rate is almost 100%. If diagnosed later, or if the disease progresses to advanced breast cancer, survival rapidly decreases. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer represents about 20% of cases, and before the introduction of HER2-targeting therapies, had the worst prognosis of all breast cancer subtypes.

The number of antibiotic-resistant strains continues to rise rapidly. Statistics from the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA) point to alarming trends that are exacerbated by fewer new antibiotics coming into the market and high costs.

It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!

It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!

The 13-valent pneumococcal conjugate vaccine (PCV13) not only prevents pneumococcal illness and death, but also dramatically decreases antibiotic-resistant infections in children by as much as 62%, according to a new study presented at IDWeek 2014

The spread of the Ebola virus (EVD) continues to capture world headlines. It has also become of great concern in the United States where 3 cases have now been confirmed.

The economic impact of an Ebola pandemic could reach $32 billion by 2015, according to the World Bank, while costs to the healthcare insurance industry will depend on how quickly the disease is controlled in countries with high insurance penetration, according to the Insurance Information Institute (III).

The biosimilar candidate ABP 501 (Amgen) has proved to be successful in treating patients with moderate-to-severe plaque psoriasis, according to results from an initial phase 3 study. ABP 501 met its primary end point for efficacy.

Narrow network plans will play an increasingly significant role in healthcare, but there are still some wildcards that could impact their success.

FDA has approved netupitant/palonosetron (Akynzeo, Eisai Inc.) to treat chemotherapy-induced nausea and vomiting (CINV).